Welcome to our dedicated page for Ocular Therapeut news (Ticker: OCUL), a resource for investors and traders seeking the latest updates and insights on Ocular Therapeut stock.
Ocular Therapeutix, Inc. (NASDAQ: OCUL) generates frequent news as an ophthalmology-focused biopharmaceutical company advancing late-stage retinal programs and a commercial eye-care product. Its press releases highlight progress across the AXPAXLI (OTX-TKI) clinical programs in wet age-related macular degeneration (wet AMD) and non-proliferative diabetic retinopathy (NPDR), as well as updates related to DEXTENZA, financings, and corporate events.
News coverage for OCUL commonly includes clinical milestones such as target randomization in the SOL-R Phase 3 wet AMD trial, completion of randomization in SOL-1, and the initiation or advancement of the HELIOS Phase 3 registrational program in NPDR. The company also issues announcements about regulatory strategy, including Special Protocol Assessment (SPA) agreements with the U.S. Food and Drug Administration for SOL-1 and HELIOS-2 and plans to leverage the 505(b)(2) pathway for AXPAXLI in wet AMD.
Investors following OCUL news will see regular business and capital markets updates, such as underwritten equity offerings, cash runway disclosures, and inducement equity grants under Nasdaq Listing Rule 5635(c)(4). The company also reports quarterly financial results and business highlights, describing clinical execution, trial timelines, and planned extension studies like SOL-X for long-term evaluation of AXPAXLI in wet AMD.
In addition, Ocular Therapeutix announces participation in scientific and investor conferences, where it presents data from earlier-stage trials (for example, HELIOS Phase 1 results in NPDR) and discusses its strategy to "redefine the retina experience." For a consolidated view of these developments, the OCUL news page on Stock Titan brings together clinical, regulatory, financial, and corporate communications so readers can track how trial outcomes, regulatory interactions, and financing activities may shape the company’s ophthalmic pipeline and commercial portfolio over time.
Ocular Therapeutix (NASDAQ: OCUL) reported Q3 2024 financial results and business updates. The company achieved total net revenue of $15.4 million, a 2.3% increase from Q3 2023. Cash position stands at $427.2 million, expected to fund operations into 2028. The Phase 3 SOL-1 trial for AXPAXLI in wet AMD is expected to complete randomization by year-end 2024, with topline data anticipated in Q4 2025. The company reported a net loss of $36.5 million or $(0.22) per share. Full-year 2024 DEXTENZA revenue guidance is projected between $62.0-67.0 million.
Ocular Therapeutix (NASDAQ: OCUL) has announced its participation in two major healthcare events. The company will present at the Jefferies London Healthcare Conference on November 20, 2024, featuring a fireside chat at 9:00 AM GMT, which will be accessible via webcast on the company's investor website.
Additionally, the company will participate in the Ophthalmology Innovation Summit XIV in San Diego on November 22-23, 2024. The event will feature three sessions: a Retina Innovation Showcase presented by Chief Strategy Officer Sanjay Nayak, a Glaucoma Spotlight panel featuring Board Member Adrienne Graves, and 'A View From The Street' panel moderated by CEO Pravin U. Dugel.
Ocular Therapeutix (NASDAQ: OCUL) has appointed Namrata Saroj, OD, as Chief Business Officer (CBO). Dr. Saroj, who previously served as Development Strategy Consultant since February 2024, brings over 20 years of experience in ophthalmic drug development and commercialization. She has contributed to successful FDA-approved drugs including LUCENTIS® and EYLEA®, and has been instrumental in executing Ocular's registrational program for AXPAXLI™ in wet age-related macular degeneration. Dr. Saroj's expertise spans clinical development, trial enrollment, launch preparation, and commercialization support across various stages of pharmaceutical development.
Ocular Therapeutix (NASDAQ:OCUL) has scheduled its third quarter 2024 financial results conference call and webcast for Thursday, November 14, 2024, at 8:00 AM ET. The company will discuss business progress and financial results for the quarter ended September 30, 2024. The event will be accessible via phone and webcast, with U.S. participants dialing 1-877-407-9039 and international participants using 1-201-689-8470. A replay will be available on the company's website for at least 30 days.
Ocular Therapeutix has announced accelerated timelines for its SOL-1 Phase 3 registrational clinical trial of AXPAXLI in wet age-related macular degeneration (wet AMD). The company now expects:
- Full enrollment and randomization by the end of 2024
- Topline data during the fourth quarter of 2025
SOL-1 is a superiority study conducted under a Special Protocol Agreement with the FDA, aiming to randomize approximately 300 subjects. The primary endpoint is the proportion of subjects maintaining visual acuity at Week 36. The ongoing Phase 3 clinical program, including SOL-1 and SOL-R studies, is expected to form the basis for AXPAXLI's regulatory filing for wet AMD treatment.
Ocular Therapeutix (NASDAQ:OCUL), a biopharmaceutical company focused on developing innovative therapies for retinal diseases and other eye conditions, has announced inducement awards for its newly appointed Chief Legal Officer, Todd D.C. Anderman. The awards, granted under Ocular's 2019 Inducement Stock Incentive Plan, include:
1. Non-statutory stock options to purchase up to 296,500 shares of Ocular's common stock at the closing price on October 7, 2024. These options have a ten-year term and vest over four years.
2. Restricted stock unit awards representing 98,700 shares of Ocular's common stock, vesting over three years in equal annual installments.
These inducement equity awards are subject to Mr. Anderman's continued service with Ocular and the terms of the 2019 Inducement Stock Incentive Plan.
Ocular Therapeutix (NASDAQ: OCUL) has announced its participation in the UBS Virtual Opthalmology Day 2024. The event will feature a fireside chat with Pravin U. Dugel, MD, Executive Chairman, President and CEO of Ocular, scheduled for Wednesday, October 2, 2024, at 3:00 PM ET.
The company, which focuses on developing innovative therapies for retinal diseases and other eye conditions, will also host investor meetings during the conference. Interested parties can access a live webcast of the fireside chat through the Investors section of Ocular's website at investors.ocutx.com.
This participation underscores Ocular Therapeutix's commitment to engaging with the investment community and sharing insights about its efforts to improve vision through advanced therapeutics.
Ocular Therapeutix (NASDAQ: OCUL), a biopharmaceutical company focused on developing therapies for retinal diseases and eye conditions, has announced inducement awards for its newly appointed Director of IT Cybersecurity, Russell Isaacs. The awards, granted under Ocular's 2019 Inducement Stock Incentive Plan, include:
1. Non-statutory stock options: 14,000 shares at market price, vesting over four years
2. Restricted stock unit awards: 4,666 shares, vesting over three years
These equity awards are designed to incentivize Mr. Isaacs' employment with Ocular and are subject to his continued service with the company. The grants comply with Nasdaq Listing Rule 5635(c)(4) and were effective as of September 9, 2024.
Ocular Therapeutix (NASDAQ: OCUL) announces multiple presentations at four major retina meetings in Portugal and Spain this September. The presentations focus on their innovative therapies for retinal diseases, particularly the axitinib hydrogel implant (OTX-TKI) for treating neovascular age-related macular degeneration (AMD) and diabetic retinopathy.
Key presentations include:
- 52-week results of OTX-TKI in AMD patients at The Retina Society meeting
- One-year results of OTX-TKI in diabetic retinopathy from the HELIOS Phase 1 trial
- Panel discussions on novel drug delivery approaches for posterior segment diseases
- 48-week safety and efficacy results from the HELIOS trial for non-proliferative diabetic retinopathy
These presentations highlight Ocular's transformation into a retina-focused company and its efforts to change the future paradigm for managing retinal vascular diseases.
Ocular Therapeutix (NASDAQ: OCUL), a biopharmaceutical company focused on improving vision through innovative therapies, has announced its participation in two upcoming investor conferences in September 2024. The company will be present at:
1. The Baird 2024 Global Healthcare Conference on Tuesday, September 10, with a fireside chat scheduled for 12:50 PM ET in New York, NY.
2. The H.C. Wainwright 26th Annual Global Investment Conference on Wednesday, September 11, featuring a fireside chat at 8:30 AM ET, also in New York, NY.
Investors can access a live webcast of the H.C. Wainwright fireside chat through the Investors section of Ocular Therapeutix's website at investors.ocutx.com.
FAQ
What is the current stock price of Ocular Therapeut (OCUL)?
What is the market cap of Ocular Therapeut (OCUL)?
